å‚è§é™„ä»¶(1115KB,1页)。
\ ã€æ‘˜è¦ã€‘:目的:探讨阿德ç¦éŸ¦è„‚é…åˆåŒ–ç–—æ²»ç–—æ¶æ€§è‚¿ç˜¤åˆå¹¶ä¹™è‚所致è‚功能ã€HBVDNAåŠå…¶ä»–化疗副å应的影å“。方法:选å–ç¬¦åˆæ ‡å‡†çš„20ä¾‹æ¶æ€§è‚¿ç˜¤åˆå¹¶ä¹™è‚患者用阿德ç¦éŸ¦è„‚åŠ TP方案(ç´«æ‰é†‡+顺铂)化疗;å¦é€‰20ä¾‹æ¶æ€§è‚¿ç˜¤åˆå¹¶ä¹™è‚患者,åªäºˆä»¥æ™®é€šæŠ¤è‚治疗和TPæ–¹æ¡ˆåŒ–ç–—ã€‚ç»“è®ºï¼šæ¶æ€§è‚¿ç˜¤å¹¶ä¹™è‚患者,æœç”¨é˜¿å¾·ç¦éŸ¦è„‚åŠæŠ¤è‚è¯ç‰©æ²»ç–—åŽè‚功能ã€HBVDNAã€ä¹™è‚两对åŠå‡è¾ƒä¸ç”¨æŠ—病毒è¯ç‰©æ²»ç–—好。
关键è¯ï¼šé˜¿å¾·ç¦éŸ¦è„‚ï¼›æ¶æ€§è‚¿ç˜¤ï¼›æ…¢æ€§ä¹™è‚ï¼›TP方案化疗Abstract: Objective: to study the adefovir fat with the treatment of m alignant tumor chemotherapy combined caused by hepatitis b liver function, HBVDNA and other side effects of chemotherapy. Methods: the standard 20 patients with m alignant tumor with hepatitis b patients with adefovir fat and TP scheme (paclitaxel plus cisplatin) chemotherapy; Cause 20 patients with m alignant tumor with hepatitis b patients, only to be common to protect liver treatment and TP scheme chemotherapy ......